Graphic Design by Presley Design Studio | Powered by Fission Content Management System | Web Development provided by 360PSG
|
David M. Margolis, M.D., F.A.C.P.
Reportable Conflicts of Interests: None
Disclosure of Financial Conflicts of Interest: None
Education:
Doctor of Medicine
Tufts University School of Medicine
Boston, MA
Bachelors of Science in Biology
Harvard University
Cambridge, MA
Post Graduate or Residency Training:
Postdoctoral Fellowship 1991-1994
Program in Molecular Medicine (laboratory of Dr. Michael R. Green, MD, PHD)
University of Massachusetts Medical Center
Worcester, MA
Infectious Diseases Fellowship
National Institutes of Health
National Institute of Allergy and Infectious Diseases
Clinical Associate, Medical Virology Section, Laboratory of Clinical Investigation, NIAID 1989-1991
Medical Staff Fellow, LCI, NIAID 1988-1989
Residency, Department of Medicine 1986-1988
Tufts-New England Medical Center
Boston, MA
Internship, Department of Medicine 1985-1986
Tufts-New England Medical Center
Boston, MA
Fellowship and Board Certifications:
Fellow, American College of Physicians, 1996
Diplomate in Infectious Diseases
American Board of Internal Medicine, 1992, 2003
Diplomate in Internal Medicine
American Board of Internal Medicine, 1988 (permanent)
Current Position or Practice Site:
Professor of Internal Medicine, Microbiology & Immunology, Epidemiology
University of North Carolina at Chapel Hill
Michael Hooker Research Center
Chapel Hill, NC
Professional Appointments:
Editorial Board, Journal of Virology, 2008-present
Editorial Board, AIDS, 2006-present
HIV Editor-in-chief, Contagion, 2004-2006
Medical Editor, National AIDS Treatment Advocacy Project, 2003-present
Medical Editor, amfAR Research Global Link, 2003-2005
Past Positions and/or Appointments:
The University of Texas Southwestern Medical School at Dallas
Chief, Infectious Diseases Section, Medicine Service, Dallas Veterans Affairs Medical Center, Dallas, TX; 2002-2005
Associate Professor of Internal Medicine, Division of Infectious Diseases, The University of Texas Southwestern Medical Center, Dallas, TX; 1999-2005
Member, Program in Molecular Microbiology; Division of Cell and Molecular Biology, The University of Texas Southwestern Medical Center, Dallas, TX; 1999-2005
Director, HIV Services, Dallas Veterans Administration Medical Center, Dallas, TX; 1999-2002
The University of Maryland
Assistant Professor, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD; 1994-99
Assistant Professor of Medicine and Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD; 1994-99
Attending Physician, Evelyn Jordan Center (HIV Clinic) and University of Maryland Medical Center, Baltimore, MD; 1994-99
Associate Member, Molecular and Cell Biology Program, University of Maryland at Baltimore Graduate School, Baltimore, 1994-99
The University of Massachusetts School of Medicine
Assistant Professor and Attending Physician, Division of Infectious Diseases and Adult HIV Clinic, University of Massachusetts Medical Center, Worcester, MA; 1991-94
Publications:
MA Moody, LK Verkoczy, MS Drinker, TC Gurley, DJ Marshall, JF Whitesides, A Dixon, A Nagel, M Williams, R Parks, MC Levesque, S Allgood, M McAdams, DM Crossman, RM Scearce, DM Margolis, J Robinson, HX Liao, SM Alam, and BF Haynes. HIV-1 Envelope Epitope Tetramers for Identification and Isolation of Antigen-Specific B Lymphocytes. Submitted
Smith KY, Zheng S, Bosch RJ, Margolis DM, Tenorio AR, Napolitano L, Pollard R, Connick E, Gross BH, Valdez H, Francis IR, Wang R, Muurahainen N, Stocker V for the AACTG 5174 Protocol Team. Treatment with Recombinant Growth Hormone is Associated with Enhanced CD4 Lymphocyte Reconstitution in HIV-Infected Subjects with Incomplete Immune Reconstitution on HAART - Results of Adult AIDS Clinical Trial Group Protocol (AACTG) 5174. Submitted
Wilkin TJ, DiRienzo G, Droll K, McKinnon J, Fletcher C, Margolis DM, Bastow B, Thal G, Woodward W, Godfrey C, Swindells S. Regimen Simplification to Atazanavir-Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression: Final 48-Week Results. Submitted
Robertson KR, Su Z, Margolis DM, Evans S, Havlir DV, Krambrink A, Skiest DJ for the A5170 study team. Neurocognitive function before and after antiretroviral treatment discontinuation in patients with immunological preservation: Neurological Sub-study of ACTG 5170. Submitted.
Archin NM, Espeseth A, Parker D, Cheema C, Hazuda DJ, Margolis DM. Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid. AIDS Res Hum Retro. In press.
Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM and the A5170 study team. Improved Measures of Quality of Life, Lipid Profile and Lipoatrophy after Treatment Interruption in HIV-Infected Patients with Immune Preservation: a substudy of ACTG 5170. J Acquir Immune Defic Syndr. In press.
Vahey MT, Wang Z, Ockenhouse CF, Su Z, Nau ME, Krambrink A, Skiest DJ, Margolis DM. Differential Expression of Genes Associated with the Regulation of Apoptosis Predicts Progression in Persons Who Discontinue Antiretroviral Therapy. AIDS Res Hum Retro. 2008; 24:1047-66.
Hare CB, Mellors J, Krambrink A, Su Z, Skiest DJ, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs R, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir, DV. Detection of NNRTI Resistant HIV-1 after Discontinuation of Virologically Suppressive Antiretroviral Therapy. Clin Infect Diseases 2008; 47:421–424.
Archin NA, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, Coffin JM, Margolis DM. Standard ART and Valproic Acid Have Limited Impact on the Persistence of HIV Infection in Resting CD4+ T Cells. AIDS 2008; 22:1131-1135.
Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV Fusion with Multivalent Gold Nanoparticles. J Am Chem Soc 2008; 130:6896-7.
Choudhary, S.K., Archin, N.M., Margolis, D.M. Hexamethylbisacetamide and Disruption of Human Immunodeficiency Virus Type 1 Latency in CD4+ T Cells. J Infectious Diseases 2008; 197:1162–1170.
Busti AJ, Bedimo R, Margolis DM, Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult, male patients after switch to atazanavir/ritonavir. J. Invest. Med. 2008; 56:539-544.
Jiang G, Espeseth A, Archin NM, Hazuda DJ, and Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting HDAC1 to the Human Immunodeficiency Virus Type 1 promoter. J. Virology 2007; 81:10914-23.
The Safety and Antiviral Activity of b-D-2,6-Diaminopurine Dioxolane (DAPD) with or without Mycophenolate Mofetil (MMF) in Multidrug-resistant HIV Infection (AIDS Clinical Trials Group study A5165). AIDS 2007; 21:2025-2032.
Skiest, D.J., Su, Z., Havlir, D.V., Robertson, K.R., Coombs, R.W., Cain, P., Peterson, T., Kambrick, A.,Jahed, N., McMahon, D., Margolis, D.M. Antiretroviral Treatment Interruption in HIV-infected Patients with Preserved Immune Function is Associated with a Low Rate of Clinical Progression: A Prospective Study. J. Infect. Diseases. 2007; 195:1426-36.
Lederman, M.M., Smeaton, L., Smith, K., Rodriguez, B., Pu, M., Wang, H., Sevin, A., Tebas, P., Sieg, S.F., Medvik, K., Margolis, D.M., Pollard, R., Ertl H.C.J., Valdez, H. In chronic HIV-1 infection, Cyclosporine A provides no sustained immunologic benefit to persons starting suppressive antiretroviral therapies – results of a randomized controlled trial of the AIDS Clinical Trials Group: A5138. J. Infect. Diseases. 2006; 194:1677–85.
Bedimo, R.J., Ghurani, R., Nsuami, M., Turner, D., Kvanli, M.B., Brown, G., and Margolis. D.M. Lipid abnormalities in HIV/HCV co-infected patients. HIV Medicine. 2006; 7:530–536.
Swindells, S, DiRienzo, G., Wilkin, T, Fletcher, C.V. Margolis, D.M., Thal, G.D., Godfrey, C., Bastow, B., Ray, M.G., Wang, H., Coombs, R.W., McKinnon, J., Mellors, J.W., for the AIDS Clinical Trials Group 5201 Study Team. A prospective, open-label pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006; 296:806-14.
Busti, A.J., Tsikouris, T.P., Peeters, M.J., Das, S.R., Canham, R.M., Abdullah, S.M., and Margolis, D.M. A prospective evaluation of the effect of atazanavir on the QTc-interval and QTc-dispersion in HIV-positive patients. HIV Medicine 2006; 7:317-320.
Kaur, R., Bedimo, R., Shaw, L., and Margolis, D.M. A placebo-controlled, double blind, pilot trial of intensification of antiviral therapy with mycophenolate mofetil. AIDS Res Ther. 2006; 3:16-20.
Klichko, V., Kaur, R.J., Archin, N., Lehrman, G, and Margolis, D.M. Hexamethylbisacetamide remodels the Human Immunodeficiency Virus type 1 promoter and induces Tat-independent HIV-1 expression without cellular activation. J. Virology. 2006; 80:4570–4579.
Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., Landay, A.L., Coombs, R.W., Richman, D.D., Mellors, J.W., Coffin, J.M., Bosch, R.J., Margolis, D.M. Depletion of latent HIV infection in vivo: a proof of concept study. Lancet 2005; 36:549-555.
Ylisastigui, L, Kaur, R, Volker, JL, Johnson, H, Hansen, U, Margolis, DM. Mitogen-Activated Protein Kinase Regulation of LSF Occupancy at the Integrated Promoter of HIV-1. J. Virology 2005; 79:5952-5962.
Kaur, RJ, Klichko, V, Margolis, DM. Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapy. AIDS Res. Hum. Retro. 2005; 21:116-124.
Ylisastigui L., Coull, J.J., Rucker V.C., Melander, C., Bosch, R.J., Brodie, S.J., Corey, L., Sodora, D.L., Dervan, P.B., and Margolis, D.M. Polyamides Reveal a Role for Repression in Viral Latency within HIV-infected Donors’ Resting CD4+ T Cells. J. Infectious Diseases. 2004; 190:1429-37.
Ylisastigui, L, Archin, N, Lehrman, G, Bosch, RJ, Margolis, DM. Coaxing Human Immunodeficiency Virus Type 1 from Resting CD4+ T Cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18:1101-1108.
Lehrman, G, Bosch, RJ, Margolis, DM. Interleukin 7 induces HIV outgrowth from the Resting CD4+ T Cells of Aviremic HIV-infected Donors. J. Acquir. Immune Defic Syndr. 2004; 36:1103-1104.
Weis, BC, Margolis, DM, Merritt, ME, Burgess, SC, Malloy, CR. Glucose production pathways by 2H and 13C NMR in patients with HIV-associated lipoatrophy. Magn Reson Med. 2004; 51:649-54.
Gould-Fogerite, S, Mannino, RJ, Margolis, DM. Cochleate Delivery Vehicles: Applications to Gene Therapy. Drug Delivery Technology 2003; 3:40-47.
Nachman, S, Kim, S, King, J, Abrams, A, Margolis, DM, Petru, A, Shearer, W, Smith, E, Moye, J, Blanchard, S, Hawkins, E, Bouquin, P, Vink, P, Benson, M, Riley, SE, Malinoski, F. Safety and Immunogenicity of a Heptavalent Pneumococcal Conjugate Vaccine in HIV Type-1 Infected Infants. Pediatrics 2003; 112:66-73.
Ruane, PJ, Parenti, DM, Margolis, DM, Shepp, DH, Babinchak, TJ, van Kempen, AS, Kauf, TL, Danehower, SA, Yau, L, Hessenthaler, SM, Goodwin, SD, and Hernandez, JE. Compact Quadruple Antiretroviral Therapy with the Lamivudine/ Zidovudine Combination Tablet Plus Abacavir/Efavirenz and the Lamivudine/ Zidovudine/Abacavir Triple Nucleoside Tablet Plus Efavirenz in Treatment-Naïve HIV-Infected Adults. HIV Clinical Trials 2003; 4:231-43.
Burgess, SC, Weis, B, Jones, JG, Smith, E, Merritt, ME, Margolis, DM, Sherry, AD, and Malloy, CR. Noninvasive Evaluation of Liver Metabolism by 2H and 13C NMR Isotopomer Analysis of Human Urine. Anal. Biochem. 2003; 312:228-34.
He, G, Margolis, DM. Counter-regulation of Chromatin Acetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 by the HIV-1 Activator Tat and the HIV-1 Repressor YY1. Mol. Cell. Biol. 2002; 22:2965-2973.
He, G, Ylisastigui, L, Margolis, DM. Chromatin Regulation of HIV-1 Expression. DNA and Cell Biology 2002; 21:697-705.
Coull, JJ, He, G, Melander, C, Rucker, V, Dervan, PB, Margolis, DM. Targeted Derepression of the Human Immunodeficiency Type 1 Virus Long Terminal Repeat by Pyrrole-Imidazole Polyamides. J. Virology 2002; 76:12349-54.
Margolis, DM, Kewn, S, Coull, JJ, Ylisastigui, L, Turner, D, Wise, H, Hossain, MM, Lanier, ER, Shaw, LM, Back, DJ. The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir is Associated with Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNA. J. Acquir. Immune Defic Syndr. 2002; 31:45–49.
Hossain MM, Coull JJ, Drusano GL, Margolis, DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res. 2002; 55:41-52.
Coull, JJ, Turner, D, Betts, M, Melby, T, Lanier, ER, Margolis, DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 2001; 26:423-434.
Hossain, MM, Margolis, DM. Inhibition of HIV Replication by A77 1726, the Active Metabolite of Leflunomide, in Combination with Pyrimidine Nucleoside Reverse Transcriptase Inhibitors. J Acquir Immune Defic Syndr. 2001; 28:199-201.
Coull, J, Romerio, F, Sun, J-M, Volker, JM, Galvin, KM, Davie, JR, Shi, Y, Hansen, U, Margolis, DM. The human factors YY1 and LSF repress the human immunodeficiency virus type-1 long terminal repeat via recruitment of histone deacetylase 1. J. Virology 2000; 74:6790–6799.
Cocchi, F, DeVico, AL, Yarchoan, R, Redfield, R, Cleghorn, F, Blattner, WA, Garzino-Demo, A, Colombini-Hatch, S, Margolis, DM, Gallo, RC. Higher macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc. Natl. Acad. Sci. USA 2000; 97:13812-13817.
Moriuchi, M, Moriuchi, H, Margolis, DM, Fauci, AS. USF/c-Myc Enhances, while Yin-Yang 1 Suppresses the Promoter Activity of CXCR4, a Coreceptor for HIV-1 Entry. J Immunol. 1999; 162:5986-92.
Margolis, DM, Heredia, A, Gaywee, J, Oldach, D, Drusano, G, Redfield, RR. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr. 1999; 21:362-370.
Heredia, A, Margolis, DM, Oldach, D, Hazen, R, Redfield, RR. Abacavir in combination with the IMPDH inhibitor mycophenolic acid, is active against multi-drug resistant HIV. J Acquir Immune Defic Syndr. 1999; 22:406-7.
Flamand, L., Crowley, RW, Lusso, P, Columbini-Hatch, S, Margolis, DM, Gallo, RC. Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc. Natl. Acad. Sci. USA 1998; 95:3111-3116.
Romerio, F, Gabriel, M, Margolis, DM. Repression of HIV-1 through the novel cooperation of the human factors YY1 and LSF. J. Virology 1997; 71:9375-9382.
Chougnet, CA, Margolis, DM, Landay AL, Kessler HA, Shearer, GM. Contribution of prostaglandin E2 to the Interleukin-12 defect in HIV-infected patients. AIDS 1996; 10:1043-1045.
Margolis, DM, Somasundaran, M, Green, MR. Human transcription factor YY1 represses HIV-1 transcription and virion production. J. Virology 1994; 68:905-910.
Straus, SE, Savarese, B, Tigges, M, Freifeld AG, Krause, PR, Margolis, DM, Meier, JL, Paar, DP, Adair, SF, Dina, D, Dekker, C, Burke, RL. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans with a recombinant glycoprotein D vaccine. J. Infect. Dis. 1993; 5:1045-1052.
Margolis, DM, Ostrove, JM, Straus, SE. HSV-1 activation of HIV-1 transcription is augmented by a cellular protein that binds near the initiator element. Virology 1993; 192:370-374.
Margolis, DM, Rabson, AB, Straus, SE, Ostrove, JM. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992; 186: 788-791.
Margolis, DM, Melnick, DA, Alling, DW, Gallin, JI. Trimethoprim-sulfamethoxazole in the management of chronic granulomatous disease. J. Infect. Dis. 1990; 162:723-726.
Willinger, M, Margolis DM. Effect of the weaver mutation on cerebellar neuron differentiation. I: Qualitative observation of neuron behavior in culture. Developmental Biology 1985; 107:156-172.
Willinger, M, Margolis, DM. Effect of the weaver mutation on cerebellar neuron differentiation. II: Quantitation of neuron behavior in culture. Developmental Biology 1985; 107:173-179.
Sidman, RL, Willinger, M, Margolis, DM. Mouse weaver mutation affects granule cell neurite growth in vitro. Birth Defects Orig Artic Ser. 1983; 19:189-200.
Willinger, M, Margolis, DM, Sidman, RL. Neuronal differentiation in cultures of weaver (wv) mutant mouse cerebellum. J. Supramol. Struct. Cell. Biochem. 1981; 17: 79-81.
Books and Chapters
Jiang G, Choudhary S, Margolis DM. Molecular mechanisms of persistent proviral HIV-1 infection. In: Persistent and Latent Infection by HIV-1 and Related Lentiviruses, Ed: AM Brown 2007: 111-126.
Margolis, DM: Resistance Testing. In: Nassar, N.N., Keiser, P., Gregg, C. Parkland Pocket Guide to HIV Care. Dallas, TX: TX/OK AETC, 2005: 45-50.
Romerio, F, and Margolis, DM: In vitro techniques for studies of HIV-1 promoter activity. In: N.L. Michael and J.H. Kim, eds. Methods in Molecular Medicine, vol. 17: HIV Protocols. Totowa, NJ: Humana, 1999: 197-203.
Other Peer-Reviewed Articles
Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Exp Rev Mol Med in press
Margolis, D.M. Confronting proviral Infection. Current HIV/AIDS Reports 2007, 4:60–64.
Margolis, D.M., Archin, N.A. Attacking HIV provirus: therapeutic strategies to disrupt persistent infection. Infect. Dis.-Drug Targets. 2006; 6:369-76.
Archin, N., and Margolis, D.M. Attacking Latent HIV Provirus: from mechanism to therapeutic strategies. Curr. Opinions HIV AIDS, 2006; 1:134-140.
Busti, A.J., Hall R., and Margolis, D.M. Atazanavir for the treatment of HIV infection. Pharmacotherapy 2004; 24:1732–1747.
Tribble, M., Gregg, C.R., Smith, J.W., Amirkhan, R.H., Margolis D.M. Fatal Cerebral Ergotism Caused by Cafergot and HIV Protease Inhibitors. Headache 2002; 42:694-95.
Margolis DM, Collins MT.: A 74-year-old man with persistent fevers. Maryland Med J. 1997; 46(10):524-9.
Bräu, N., Leaf, H.L., Wieczorek, R.L., Margolis, D.M. Severe hepatitis in three AIDS patients treated with the protease inhibitor indinavir. Lancet 1997, 349:924-925.
Clark, JA, Margolis, DM. A cutaneous lesion due to Mycobacterium Avium complex: an unusual presentation in an AIDS patient. Clin. Inf. Dis. 1993; 16: 655-657.
Davey, RC, Margolis, DM, Kleiner, DE, Travis WD, Masur, H.: Digital necrosis and disseminated pneumocystis carinii. Ann. Int. Med. 1989; 111(8): 681-682.
Margolis, DM, Ross, E, Miller, KB: Rhabdomyolysis associated with high-dose cytarabine. Cancer Treatment Reports 1987; 71(12): 1325-1326.
Editorials and Letters
Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz R. The Challenge of a Cure for HIV Infection. Submitted
Margolis DM. Treatment for lipoatrophy: facing the real costs. AIDS. 2007; 21:1819-2.
Margolis DM and Archin NM. Eliminating Persistent HIV Infection: Getting to the End of the Rainbow. J Infect Dis. 2007; 195:1734-6.
Margolis, D.M. Low-level viremia and low-level anxiety: Defining the clinical comfort zone. Contagion 2005; 2 (11): 457-458.
Margolis, D.M. Bashing the cell to kill the virus: inhibition of human enzymes as an alternate antiviral strategy. Contagion 2005; 2 (7): 334-335.
Bedimo, R., Margolis, D.M. Challenges of non-AIDS-defining cancers among HIV-infected patients. Contagion 2005; 2(2):71-73.
Margolis, D.M. Drug resistance patterns and selecting or revising antiretroviral therapy. Contagion 2004; 1(1): 29-31.
Margolis, D.M. Interferon inactivator(s) in patients with AIDS and AIDS-unrelated Kaposi's sarcoma. Am J Med. 1987; 82(6): 1278.
Published Abstracts
Induction of B Cell Polyclonal Differentiation and Apoptosis With Massive Gastrointestinal Tract Germinal Center Loss In the Earliest Stages of HIV-1 Infection. Barton F. Haynes, M. Anthony Moody, Marc C. Levesque, Kwan-Ki-Hwang, George M. Shaw, Georgia Tomaras, Charles Hicks, Martin Markowitz, Thomas Kepler, Supriya Munshaw, Garnett Kelsoe, David Margolis, and Hua-Xin Liao, Keystone Symposium on HIV Vaccines. Banff, Alberta, Canada. April 2009.
Differential Representation of HIV-1 gp41 Immunodominant Versus Membrane Proximal Epitope-Specific B Cells in Subjects Chronically Infected with Clade B HIV-1. MA Moody, TC Gurley, S Allgood, PD McNair, MS Drinker, HX Liao, M Markowitz, D Margolis, CB Hicks, SM Alam, DJ Marshall, JF Whitesides, MC Levesque, BF Haynes. Center for HIV-AIDS Vaccine Immunology (CHAVI) Annual Meeting, Durham, NC, September 2008.
HIV RNA in GALT does not correlate with Plasma HIV RNA levels in Acute HIV Infection DC Parker, NM Archin, A Sugarbaker, N Shaheen, J Eron, L Ngo, J Kuruc, C Hicks, S Fiscus, C Gay, M Kerkau, S McCoy, K McGee, JF Whitesides, J Schmitz, Cohen MS, and DM Margolis. Center for HIV-AIDS Vaccine Immunology (CHAVI) Annual Meeting, Durham, NC, September 2008.
Efficacy of NNRTI-Based Antiretroviral Therapy initiated during Acute HIV Infection. C Gay, A Johnson, S McCoy, J Kuruc, K McGee, L McNeil, M Kerkau, C Pilcher, D Margolis, P Leone, S Fiscus, G Ferrari, C Hicks, J, The Duke-UNC Acute HIV Infection Consortium. Persistent Viremia Despite Long-term Suppressive Antiretroviral Therapy (ART). AIDS 2008 - XVII International AIDS Conference, Mexico City, Mexico August 2008.
Baseline Results from ACTG 5244: Persistent Viremia Despite Long-term Suppressive Antiretroviral Therapy (ART): Gandhi RT, Palmer S, Bosch R, Zheng S, Demeter L, Leavitt R, Margolis D, Read S, Coffin J, Mellors J, Eron J for the A5244 team. AIDS 2008 - XVII International AIDS Conference, Mexico City, Mexico August 2008.
Differential Expression of Genes Associated with Apoptosis Predicts CD4 Decline after Interruption of ART in ACTG A5170. M Vahey, Z Wang, Z Su, A Krambrink, D Skiest, and D Margolis. 15th Annual Conference on Retroviruses and Opportunistic Infections, Boston MA, February 2007; abstr. 339.
Absence of Protease Resistance with Virologic Rebound by Single Genome Sequencing on Atazanavir/Ritonavir as Simplified Maintenance Therapy: ACTG 5201. McKinnon J, T Wilkin, S Swindells, G DiRienzo, C Fletcher, D Margolis, G Thal, B Bastow, K Droll, J Mellors, and the A5201 Study Group. 15th Annual Conference on Retroviruses and Opportunistic Infections, Boston MA, February 2007; abstr. 890.
HIV-1 Inhibition with Multi-valent Gold Nanoparticles. MC Bowman, E Ballard, C Akerson, J D'Antonio, D Feldheim, C Melander, and D Margolis. 15th Annual Conference on Retroviruses and Opportunistic Infections, Boston MA, February 2007; abstr. 744.
Diagnosing Acute HIV Infection in North Carolina: Challenges and Opportunities. K McGee, S Kim, A Johnson, J Kuruc, S McCoy, L McNeil, C Gay, D Margolis, J Eron, and C Hicks. 15th Annual Conference on Retroviruses and Opportunistic Infections, Boston MA, February 2007; abstr. 699.
The North Carolina CHAVI Cohort: the first 14 months. Hicks C, Gay C, Margolis D, McGee K, Kuroc J, Beagle S, Kerkau M, Fiscus S, McCoy S, Leone P, Eron J. Center for HIV-AIDS Vaccine Immunology (CHAVI) Annual Meeting, Durham, NC, September 2007.
Resting CD4+ T cell infection in acute HIV infection reflects early control of viral replication. NM Archin, J Eron, L Ngo, J Kuruc, C Hicks, N Bandarenko, S Fiscus, C Gay, M Kerkau, S McCoy, K McGee, J Whitesides, J Schmitz, Cohen MS, and DM Margolis. Center for HIV-AIDS Vaccine Immunology (CHAVI) Annual Meeting, Durham, NC, September 2007.
Antiretroviral Treatment of Acute HIV Infection: Symptomatic bias, cytokines and chemokines. Cohen, MS, Gay, C, Stacey, A, Dibben, O, McCoy, S, Kuruc, J, McGee, K, Fiscus, S, Margolis, D, Eron, J, Hicks, C, Borrow, P. Center for HIV-AIDS Vaccine Immunology (CHAVI) Annual Meeting, Durham, NC, September 2007.
Chronically HIV-1 infected subjects have detectable peripheral blood memory B cells to gp140 envelope but not to the gp41 membrane proximal external region 2F5 epitope. M Bonsignori, MA Moody, MS Drinker, SM Alam, E Petzold, CB Hicks, DM Margolis, N Archin, JF Whitesides and BF Haynes. AIDS Vaccine 2007 Conference; August 2007; Seattle WA.
Patient reported symptoms improve following prolonged treatment interruption: ACTG 5170 quality of life results. Skiest D., Krambrink A., Su Z., Robertson K., Havlir D., Margolis D. 4th IAS Conference, Sydney, Australia, July 2007.
Standard ART and Valproic Acid have Limited Impact on Persistent HIV Infection of Resting CD4+ T Cells. NM Archin, J Eron, S Palmer, L Ngo, A Hartmann Duff, N Bandarenko, J Schmitz, A Wiegand, JM Coffin, AL Landay, RJ Bosch, Cohen MS, DM Margolis. 16th International HIV Drug Resistance Workshop, Barbados, June 2007.
This Is Your Brain Off Drugs: Neurocognitive Function before and after ART Discontinuation in Patients with High CD4 Nadir (ACTG A5170). K Robertson, Z Su, A Krambrink, S Evans, D Havlir, D Margolis, D Skiest, and ACTG 5170 team. 14th Annual Conference on Retroviruses and Opportunistic Infections, Los Angeles CA, February 2007; abstr. 113.
c-Myc and Sp1 Recruit Histone Deacetylase-1 to the HIV-1 Promoter: Combinatorial Mechanisms Maintain Latency. G Jiang, A Espeseth, D Hazuda, and D Margolis. 14th Annual Conference on Retroviruses and Opportunistic Infections, Los Angeles CA, February 2007; abstr. 225.
Expression of Latent HIV Induced by a Selective Class I HDAC Inhibitor. N Archin, A Espeseth, A Duff, M Cheema, D Parker, D Hazuda, and D Margolis. 14th Annual Conference on Retroviruses and Opportunistic Infections, Los Angeles CA, February 2007; abstr. 501.
In Chronic HIV-1 infection, Cyclosporine A Provides No Sustained Immunologic Benefit to Persons Starting ART. M Lederman, L Smeaton, K Smith, B Rodriguez, H Wang, P Tebas, S Sieg, D Margolis, C Pilcher, H Valdez, and AIDS Clinical Trials Group A5138 team. 14th Annual Conference on Retroviruses and Opportunistic Infections, Los Angeles CA, February 2007; abstr. 129.
Attacking latent HIV: towards eradication of HIV infection. Archin N, Hartmann Duff A, Eron J, Ngo L, Bandarenko N, Schmitz J, Leone P, Pilcher C, Jiang G, Hicks CB, Wohl D, Fiscus S, Swanstrom R, Cohen M, Margolis D. AIDS 2006 - XVI International AIDS Conference, Abstract no. TUPE0059.
Treatment with recombinant human growth hormone (r-hGH) leads to increased thymic output in HIV-Infected subjects with incomplete immune rReconstitution on highly active antiretroviral therapy (HAART). Smith K., Zheng L., Bosch R., Margolis D., Tenorio A., Napolitano L., Pollard R., Connick E., Gross B., Frances I., Wang R., Muurahainen N., Stocker V., ACTG Protocol Team. AIDS 2006 - XVI International AIDS Conference. Abstract no. MOAX0403.
Resistance Mutations to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) After Discontinuation of a Virologically Suppressive Regimen. CB Hare, J Mellors, A Krambrink, Z Su, D Skiest, D Margolis, S Patel, D Barnas, L Frenkel, R Coombs, F Aweeka, G Morse, D Haas, R Kim, V Boltz, S Palmer, J Coffin, DV Havlir. 15th International HIV Drug Resistance Workshop, Sitges, Spain, June 2006.
Multi-Genome Sequencing (MGS): A New, Sensitive Method of Detecting Low Frequency Drug–Resistant Mutants. D Barnas, Mary Kearney, V Boltz, S Patel, F Maldarelli, B Hare, D Havlir, Z Su, A Krambrink, D. Margolis, S Palmer, J Coffin, and J Mellors. 15th International HIV Drug Resistance Workshop, Sitges, Spain, June 2006.
A Phase I/II Randomized, Double-blind, Placebo-controlled Pilot Study of beta-D-2,6-Diaminopurine Dioxolane Vs DAPD + Mycophenolate Mofetil in Treatment-experienced Subjects (ACTG 5165). D 3th Annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006.
Differences in Calculated Glomerular Filtration Rates in Efavirenz- or Tenofovir-treated Adults in ESS4000613th Annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006.
Induction of HIV-1 expression in latently infected cell lines and inhibition of Primary Blood Cell Infection by HMBA. V. Klichko, R. Kaur and D.M. Margolis. Keystone Symposium HIV Pathogenesis. Banff, Alberta, Canada. April 2005.
Treatment with growth hormone leads to improvement in total and naïve CD4 lymphocyte recovery in HIV-infected subjects with incomplete immune reconstitution on HAART. Smith K., Wang R., Bosch R., Margolis D., Tenorio A., Pollard R., Stocker V., Gross B., Frances I., Muurahainen N., ACTG Protocol Team A. The 3rd IAS Conference on HIV Pathogenesis and Treatment, 2005. Abstract no. TuOa0203.
ABC Hypersensitivity Reactions Are Heralded by Transient Declines in Circulating CD4+ Cell Counts B. Rodriguez, H. Valdez, C. Loupa, K. Shina, D. Margolis, C. Pilcher, K Smith, T. Scott, K. Harold, M. M. Lederman. 44th ICAAC, Washington, DC, November 2004.
Lipid abnormalities in HIV/HCV co-infected patients. R.J. Bedimo, D. Turner, N. Malanda, M.B. Kvanli, H.Wise, D. Margolis. 42nd IDSA, Boston, MA, October 2004.
Determinants of replication capacity (RC) in HIV-1 isolates from ART-experienced adults failing a PI based regimen. RH Haubrich, J Hernandez, M Bates, M Thompson, D Margolis, K Pappa, L Yau, R Schooley. 15th International AIDS Conference, Bangkok Thailand, July 2004.
Late Breaker: Coaxing Human Immunodeficiency Virus Type 1 from Resting CD4+ T Cells: valproic acid induces latent viral expression. DM Margolis, G Lehrman, NM Archin, L Ylisastigui, MB Kvanli, D Turner, J Wagner, H Wise, and RJ Bosch. 11th Annual Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2004.
Late Breaker: Towards Depletion of the Resting CD4 Cell Reservoir of HIV-1. Ylisastigui L, Johnson H, Margolis, DM. 10th Annual Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2003.
Effect of Amprenavir Hyper-susceptibility on the Response to APV/Ritonavir-based Therapy in ART-experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-week Data. R Schooley, R Haubrich, M Thompson, D Margolis, S Schneider, D Richman, K Pappa, L Yau, S Hessenthaler, J Hernandez. 10th Annual Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2003.
Virologic Response to Amprenavir (APV)/Ritonavir (RTV)-based regimens in NNRTI naïve or experienced adults selected by baseline susceptibility (ESS40006): 24-wk data. R Haubrich, M Thompson, D Margolis, S Schneider, R Schooley, D Richman, K Pappa, A Pierce, L Yau, S Hessenthaler and J Hernandez. International Workshop for the Treatment of ART-Experienced Patients, San Diego, CA, September 2002.
Host factors that downregulate HIVLTR expression may establish or maintain quiescent infection in T cells. Margolis, DM , Ylisastigui L, Rucker V, Bosch, R., Dervan P, and Sodora D. 11th International HIV Drug Resistance Workshop , Seville, Spain, July 2002.
Towards therapy for the reservoir of human immunodeficiency virus type 1 in resting T cells. Margolis, DM, Johnson H, Ylisastigui L, Rucker V, and Dervan P. XIVth International AIDS Conference, Barcelona, Spain, July 2002.
Derepression of HIV LTR by pyrrole-imidazole polyamides in resting CD4+ T cells. Ylisastigui L, Wozniakowski A, Johnson H, Rucker V, Dervan P, Sodora D and Margolis, DM. Retroviruses, Cold Spring Harbor, NY, May 2002.
Exposing the Latent Reservoir of Human Immunodeficiency Virus Type 1 via Blockade of Host Repressors. David M. Margolis, Guocheng He, Loyda Ylisastigui, Victor C. Rucker, and Peter B. Dervan. 9th Annual Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002.
Combivir/Abacavir/Efavrienz- Preliminary 48-week results (COL 30336). Parenti, D., Ruane, P., Margolis, D., Van Kempen, A., Kauf, T., Danehower, S., Yau, L., Hessenthaler, S., Hernandez, J. 39th Annual Meeting of the Infectious Disease Society of America, San Francisco, CA, October 2001.
The Addition of Mycophenolate Mofetil to Antiretroviral Therapy including Abacavir Can Decrease HIV-1 RNA and Deplete Intracellular dGTP. Margolis, DM, Hossain, MM, Shaw, L, and Back, D. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, AZ, June 2001.
The Latent Reservoir of Human Immunodeficiency Virus Type 1 Infection is Maintained by Host Transcription Factors. Coull, J.J., He, G., Melander, C., Rucker, V., Dervan, P.B., Margolis, D.M. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, AZ, June 2001.
Mycophenolate Mofetil (MMF) Induces a Decrease in HIV-1 RNA Associated with Guanosine Depletion. Margolis, DM, Hossain, MM, Shaw, L, and Back, D. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001.
Low concentrations of mycophenolic acid augment the in vitro antiretroviral activity of Abacavir (ABC), Didanosine (DDI), Tenofovir (TFV), and the combination of ABC and DDI. Hossain, MM, Margolis, DM. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001.
Reduced activation and apoptosis of peripheral CD3+ / CD4+ T cells persists after viral rebound in AIDS patients treated with mycophenolate mofetil (MMF). Coull, J.J., Margolis, DM. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001.
Transcriptional Repression of the Human Immunodeficiency Virus Type-1 Long Terminal Repeat via Recruitment of Histone Deacetylase-1. Coull, J, Romerio, F, Sun, J-M, Volker, JM, Galvin, KM, Davie, JR, Shi, Y, Hansen, U, Margolis, DM. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001.
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1. Coull, J.J., Betts, M., Turner, D., Melby, T., Lanier, E.R., Margolis, DM. 4th International Workshop on HIV Drug Resistance & Treatment Strategies, Sitges, Spain, June 2000.
In Vitro Synergistic Antiretroviral Activities of Abacavir/Mycophenolic acid and DDI/Resveratrol Combinations Against Multi-drug Resistant HIV-1 (RT Mutants) Suggest a New Aproach to Control Resistance. Heredia, C. Davis, D. Margolis, D. Oldach, R. Hazen, N. Le, and R. Redfield. Keystone Symposia: Novel Biological Approaches to HIV-1 Infection Based on New Insights into HIV Biology, Keystone, CO. April 2000.
Phase 1 Pilot Study of Mycophenolic Mofetil and Abacavir in Patients with Multi-drug Resistant Virus. Robert Redfield MD, Charles Davis MD, Alonso Heredia PHD, David Margolis MD, and David Oldach MD. Keystone Symposia: Novel Biological Approaches to HIV-1 Infection Based on New Insights into HIV Biology, Keystone, CO. April 2000.
Selective Repression of HIV-1 Transcription by the Cooperation of Two Host Cellular Factors: a Mechanism for the Maintenance of Quiescent Viral Reservoirs?. Coull, J., Romerio, F., Sun, J.-M., Volker, J.M., Galvin, K.M., Davie,J.R., Shi, Y., Hansen, U., Margolis, DM. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2000.
A pilot study of the use of Mycophenolate Mofetil (MMF) as a component of therapy for multidrug resistant HIV-1. J.J. Coull, M. Betts, D. Turner, T. Melby, E.R. Lanier, and D.M. Margolis. Abstr. 1173, 39th ICAAC, San Francisco, CA September 1999.
Stable gene transfer to CD34+ cells augmented by coordinated non-viral delivery of AAV components. Gould-Fogerite, S., Cottler-Fox, M., Mannino, R., and Margolis, D.M. American Society for Gene Therapy meeting, Washington D.C., June 1999.
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. Margolis, D.M., Heredia, A., Hazen, D.J., Oldach, D., Drusano, G., Redfield, R.R. 3rd Annual Symposium on HIV Drug Resistance, San Diego, CA. June 1999.
Host Cell Factors Repress HIV-1 Gene Expression: mechanisms for viral latency. Coull, J., Davie, J., Shi, Y., Hansen, U., and Margolis, D.M. Infectious Disease Society of America 37th annual meeting, Denver, CO, November, 1998.
Development of a tissue culture method to isolate replication-competent drug-resistant viral variants in the peripheral blood lymphocytes of untreated HIV-1 infected individuals. Heredia, A., Margolis, D.M, Fantry, L., Redfield, R.R. 3rd Annual Institute of Human Virology meeting. Baltimore, MD; August 1998.
Selective Repression of HIV-1 Transcription by the Cooperation of Two Host Cellular Factors: a Mechanism for the Maintenance of Quiescent Viral Reservoirs. Romerio, F., Galvin, K., Volker, J., Shi, Y., Hansen, U., and Margolis, D.M. Keystone Symposia: HIV Pathogenesis; Park City, UT, March 1998.
Regulation of cooperative repression of HIV-1 transcription by host factors YY1 & LSF. Fabio Romerio and David M. Margolis. 4rth Conference on Retroviruses and Opportunistic Infections, Washington, DC, February 1997.
Turning on the CD4 gene in CD8+ cells: implications in HIV pathogenesis. Flamand, L., Crowley, R.W., Lusso, P., Margolis, D.M., and Gallo R.C. Institute of Human Virology annual meeting, September 1996.
Repression of HIV-1 transcription by the human transcription factor YY1. Romerio, F., Gabriel, M., and Margolis, D.M. Institute of Human Virology annual meeting, September 1996.
Repression of HIV-1 transcription by the human transcription factor YY1. Romerio, F., and Margolis, D.M. Retroviruses, Cold Spring Harbor, May 1996.
Downregulation of HIV-1 expression by the transcription factor YY1. Margolis, D.M., Somasundaran, M., Shi, Y., and Green, M.R. 9th International Conference on AIDS. Berlin, June 1993.
The role of DNA binding motifs in the transactivation of the HIV LTR by HSV-1. Margolis, D.M., Parrott, C., Leonard, J., Rabson, A.B., Ostrove, J.M. UCLA Symposia on Molecular and Cellular Biology, March 1990. J. Cell. Biochemistry 1990; Suppl. 14D: 123.
The role of HSV-1 in the transactivation of the HIV LTR. Margolis, D.M., Rabson, A.B., Ostrove, J.M. 15th International Herpesvirus Workshop. Washington D.C., August 1990.
Presentations:
Mechanisms that Maintain Proviral Latency: Targets for Future Therapeutics. Third International Workshop on HIV Persistence during Therapy, St Maarten, December 2007.
Attacking latent HIV: towards therapies for persistent HIV infection. 10th Annual International Meeting of the Institute of Human Virology. Baltimore, MD. November 2006.
Targeting the Reservoir. Symposium on HIV Treatment. 44th Annual Meeting of the IDSA. Toronto, CA, October 2006.
Opportunities in translational research: HIV as a paradigm. Keynote address: Texas Tech Health Sciences Center Annual Research Day, Amarillo, TX. August 2006.
Histone deacetylase inhibition: towards eradication of HIV infection. Case CFAR conference, Cleveland, OH, June 2006.
Predictors of HIV Disease Progression in Patients Who Stop ART with CD4 Cell Counts >350 cells/mm3 13th Annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006.
William J. Way lecture, Duke University School of Medicine, “Towards eradication of HIV infection.” January 2006.
Histone deacetylase inhibition in vivo depletes latent HIV infection. D.M. Margolis. Second International Workshop on HIV Persistence during Therapy. Saint Martin, FWI, December 2005.
Rapid Depletion of Latent HIV infection in vivo. D.M. Margolis. Plenary lecture. West Coast Retrovirus meeting. Palm Springs, CA. October 2005.
Treatment with Growth Hormone Leads to Improvement in Total and Naïve CD4 Lymphocyte Recovery in HIV-Infected Subjects with Incomplete Immune Reconstitution on HAART. Smith, K., Margolis, D.M., and ACTG 5174 study team. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil July 2005.
Chromatin deacetylation does not precede waning of HIV expression. N.M. Archin and D.M. Margolis. Keystone Symposium on HIV Pathogenesis. Banff, Alberta, Canada. April 2005.
Towards Eradication of HIV Infection. D.M. Margolis. Immune restoration Think Tank IX: the Dobson Project. San Francisco, CA, October 2004.
Targeting Reservoirs of Human Immunodeficiency Virus Infection: inducing latent viral expression without host cell activation. D.M. Margolis. 13th International HIV Drug Resistance and Therapies Workshop. Tenerife, Spain, June 2004.
Mycophenolate and Cyclosporine in HIV Therapy. D.M. Margolis. NIAID Workshop: Assessment of Future Developments in Immune Based Therapies in HIV Infection. Landsdowne, MD. January 2004.
The blockade of transcriptional repression at the HIV LTR allows outgrowth of virus from the resting T cells of aviremic patients. D.M. Margolis. First International Workshop on HIV Persistence during Therapy. Saint Martin, FWI, December 2003.
Derepression by DNA-binding Polyamides Allows Outgrowth of Human Immunodeficiency Type 1 from Resting CD4+ T Cells: Regulators of HIV Latency. D.M. Margolis. Keystone Symposium Twenty Years of HIV Research: From Discovery to Understanding. Banff, Alberta. March 2003.
Polyamides induce Derepression of HIV within Primary Resting T Cells. D.M. Margolis. Keystone Symposium on Drug Target Validation: Gene Suppression. Tahoe City, CA, Jan. 2003.
New targets in HIV therapies. D.M. Margolis. amfAR Think Tank. Dedham, MA. Dec. 2002.
Adjuvant Therapy. D.M. Margolis. International Workshop for the Treatment of ART-Experienced Patients. San Diego, CA, September 2002.
Host transcription factors maintain the stable latent reservoir HIV-1 infection. D.M. Margolis. Viral Reservoirs/Transient Infection Think Tank in HIV/AIDS: Basic Science Division, Division of AIDS, NIAID, NIH. Bethesda, MD, June 2002.
Therapeutic Modulation of Host Cell Factors. D.M. Margolis. 6th UCSF Symposium on Antiviral Chemotherapy. San Francisco, CA, April 19-20, 2002.
Late Breaker Oral Presentation: Analysis of Gluconeogenesis Using Stable Isotopes in Patients with HIV. Weis, B.C., Margolis, D.M., Merritt, M., E., Burgess, S.C., and Malloy, C.R. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002.
Localization of Histone Deacetylase 1 at the Promoter of Inactive Integrated Human Immunodeficiency Virus Type 1. He, G., Coull, J.J., Margolis, DM. Keystone Symposia: HIV Pathogenesis, Keystone, CO. April 2001.
Selective Repression of HIV-1 Transcription by the Cooperation of Two Host Cellular Factors: a Mechanism for the Maintenance of Quiescent Viral Reservoirs. Romerio, F., Sun, J.M., Coull, J.J., Galvin, K., Volker, J., Davie, J., Shi, Y., Hansen, U., and Margolis, D.M. 3rd Annual Meeting Institute of the Human Virology. Baltimore, MD; August 1998.
Repression of HIV-1 through the novel cooperation of YY1 and LSF. Romerio, F., Gabriel, M., and Margolis, D.M. 2rd Annual Meeting Institute of the Human Virology. Baltimore, MD; August 1997.
(Last updated: 2/9/2009)
|
|
